Skip to main content

Kurin Push-Button Needle FDA Cleared

NEW YORK – Blood culture collection firm Kurin said on Tuesday that the US Food and Drug Administration has cleared the firm's novel push-button needle.

"Development of our proprietary needle provides us vertical integration and also allows us to offer superior options to our customers," Kurin CEO Bob Rogers said in a statement.

The San Diego-based firm said that its specimen discard technology automatically and passively "sidelines" potential contaminants during the blood culture collection process, reducing false-positive test results that may provide wrong information to physicians.

Kurin received FDA clearance for its Kurin Lock blood culture collection product with a peripheral IV infusion set in January 2019.